Medicus Pharma Ltd.

Medicus Pharma Ltd. (NASDAQ:MDCX) is a precision guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutic assets designed to transform the standard of care. The company is actively engaged in multiple countries spread over three continents.

Our strategy is to advance select programs through Phase 2 proof-of-concept and pursue licensing or strategic partnerships with established pharmaceutical companies that are best positioned to conduct late-stage development and commercialization. Our Phase 2 studies are designed to generate decision-grade clinical, regulatory and operational data packages intended to support partnering discussions and potential licensing transactions.

We look into opportunities where an unmet need exists for improved patient safety and efficacy.

The Company is currently advancing the clinical development program of its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC).

Medicus is also developing Teverelix, a next generation GnRH Antagonist as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer.

D-MNA and Teverelix, collectively represent ~$8 billion in potential market opportunity.